|1.||Cardoso, Maria Cecilia de Almeida: 1 article (11/2014)|
|2.||Werneck, Caio: 1 article (11/2014)|
|3.||Sartorio, Cassio: 1 article (11/2014)|
|4.||Fontoura, Paula: 1 article (11/2014)|
|5.||Ramos, Cristiane Fonte: 1 article (11/2014)|
|6.||Erthal-Martins, Maria Cecilia: 1 article (11/2014)|
|7.||Besson, Françoise: 1 article (12/2013)|
|8.||Benichou, Emmanuel: 1 article (12/2013)|
|9.||Brevet, Pierre-François: 1 article (12/2013)|
|10.||Matar, Gladys: 1 article (12/2013)|
10/01/1994 - "Pituitary adenylate cyclase-activating polypeptide receptors of types I and II and glucagon-like peptide-I receptors are expressed in the rat medullary carcinoma of the thyroid cell line 6/23."
10/01/1994 - "The expression of the messenger RNAs coding for glucagon-like peptide-I (GLP-I) receptor, VIP receptor, and pituitary adenylate cyclase-activating polypeptide (PACAP) receptor as well as the expression of the receptor proteins were demonstrated in the rat medullary carcinoma of thyroid cell line 6/23 by the following experiments: 1) RNA extraction, reverse transcriptase, and polymerase chain reaction with specific primers; 2) binding of the radiolabeled ligands [125I]GLP-I-(7-36)-NH2, [125I]PACAP-(1-27), and [125I]VIP and inhibition by, respectively, unlabeled GLP-I-(7-36)-NH2, PACAP-(1-27), and VIP; and 3) study of adenylate cyclase activation by the peptides and selective inhibition of the VIP/PACAP response by the antagonist [D-Phe2]VIP. "
|3.||Type 2 Diabetes Mellitus (MODY)
07/01/1997 - "Extrapancreatic action of truncated glucagon-like peptide-I in Otsuka Long-Evans Tokushima Fatty rats, an animal model for non-insulin-dependent diabetes mellitus."
09/01/1993 - "Agonists of the glucagon-like peptide I receptor have been proposed as new therapeutic agents in NIDDM."
08/01/1996 - "Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas."
09/01/1993 - "At pharmacological doses, infusion of glucagon-like peptide I but not gastric inhibitory peptide, can ameliorate postprandial insulin secretory response in NIDDM patients. "
09/01/1993 - "Glucagon-like peptide-I and the control of insulin secretion in the normal state and in NIDDM."
10/15/2012 - "We show that the IRDye 800CW-RGD peptide: (i) specifically binds to integrin receptors; (ii) is selectively localized to glioblastoma tissue with overexpressed integrin receptors and is retained over prolonged periods of time; (iii) is associated with minimal autofluorescence and photobleaching because of imaging at 800 nm; (iv) provides delineation of tumor tissue with high precision because of a high tumor-to-normal brain fluorescence ratio (79.7 ± 6.9, 31.2 ± 2.8, and 16.3 ± 1.3) in the U-87 MG, RCAS-PDGF, and TS543 models, respectively; P < 0.01); and (v) enables fluorescence-guided glioblastoma resection. "
12/15/1997 - "Third, both Ag-specific, MHC class II (DQ)-restricted CD4+ and MHC class I-restricted (HLA-A2) CD8+ T cell lines were generated from a single patient with duodenal carcinoma whose primary tumor contained a Val12 mutation when cultured on the immunizing 13-mer peptide or a nested 10-mer peptide [i.e., ras5-14(Val12)], respectively. "
05/01/2008 - "Using immunohistochemistry, we found that the distributions of Cancer borealis tachykinin-related peptide I (CabTRP I), crustacean cardioactive peptide (CCAP), proctolin, red pigment concentrating hormone (RPCH) and tyrosine hydroxylase (dopamine) were similar to those of other decapods. "
02/25/1994 - "["Glucagon-like peptide I": a therapeutic alternative for diabetes mellitus?]."
08/01/1995 - "Glucagon-like peptide-I (GLP-I) is a potent incretin hormone that is now considered as a new therapeutic tool in the treatment of diabetes mellitus. "
04/01/1994 - "Glucagon-like peptide-I (GLP-I) is a potent incretin hormone and is considered as a new therapeutic tool in the treatment of diabetes mellitus. "
|3.||Pituitary Adenylate Cyclase-Activating Polypeptide Receptors
|4.||Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP)
|5.||Vasoactive Intestinal Peptide Receptors (Vasoactive Intestinal Peptide Receptor)
|6.||RNA (Ribonucleic Acid)
|7.||RNA-Directed DNA Polymerase (Reverse Transcriptase)
|8.||Proteins (Proteins, Gene)
|10.||Adenylate Cyclase (Adenylyl Cyclase)